leisure time -WSS

leisure time

author：Wikipedia 2025-09-28 21:56:43 - browse：4

Pfizer on Friday said it was stopping development of a twice-daily oral obesity medication after an underwhelming clinical trial, a blow to the company’s efforts to compete in the booming field of weight-loss medications.

The medicine, danuglipron, met its primary target in a placebo-controlled Phase 2b trial, leading to a statistically significant amount of weight lost, the company said. But the weight reductions were smaller than those seen in trials of rival medicines targeting the same GLP-1 pathway, and a high rate of patients experienced side effects and dropped out of the trial.

Pfizer said it would not move twice-daily danuglipron into Phase 3 trials, but that instead it would focus on a once-daily formulation, which is currently undergoing pharmacokinetic studies. Data are expected in the first half of 2024.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Novo acquires Inversago for up to $1 billion

focus

explore

WSS

Ebola vaccine can save some who are already sick, per new study

Having children helps parents live longer, especially after age 80

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Why don't Americans have at

Maui funeral service workers on devastation of fires: 'I'm in shock'

Timeline: Special counsel's investigation into Trump's handling of classified documents

hotspot

leisure time

hotspot

Hollywood unions extend contract negotiations for actors

Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

Virginia high school admissions case could be legal follow

Newly revealed memo details efforts to keep Trump in power following election loss

State Dept. review finds Biden bears some blame for Afghanistan failures

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

Psychedelics group wrestles with new pharma identity

Some of the ways extreme heat will change life as we know it

New air purifier tech could be key to improving indoor air quality

Newly revealed memo details efforts to keep Trump in power following election loss

Wikipedia

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

ACIP vaccine advisory panel sees its vacancies filled

Readout Newsletter: Replicate, Biogen's Leqembi, and Humira

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Artificial intelligence use in health care faces greater scrutiny in 2024

focus

hotspot

explore

leisure time